Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes

Heart failure with preserved ejection fraction (HFpEF) is a common disease with high morbidity and lacks effective treatment. We investigated the protective effects of the long-term application of the sodium-g...

Source: Diabetology and Metabolic Syndrome - June 29, 2023 Category: Endocrinology Authors: Bin Feng, Peiran Yu, Hao Yu, Buyun Qian, Yuan Li, Kangyun Sun, Bimin Shi, Nannan Zhang and Guidong Xu Tags: Research Source Type: research